EGFR and cancer: Ibrutinib (Imbruvica) has been approved for the treatment of certain types of cancers, however, there are several side effects, such as diarrhea, arterial fibrillation and bleeding, which have been partially attributed to off-target effects on the epidermal growth factor receptor and the Tec family proteins other than BTK [108, 109].